Close Menu
May 27, 2020
Sponsored by
PierianDx

Analyzing Complex Genomic Variants in Somatic Cancer

Partner Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Next generation sequencing (NGS) technologies facilitate the accurate detection of genetic variants. Yet, the process of analyzing and classifying more complex alterations remains challenging.  In this educational webinar, we focus on gene fusions, co-occurring variants, copy number variants, and tumor mutational burden (TMB), and we provide practical strategies for analyzing and classifying these complex variants in the context of somatic cancer.

Sponsored by

Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.

Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.

Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.

In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
22
Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

Jul
29
Sponsored by
Illumina

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell.